华法林药物基因组学和个体化用药

被引：29

作者：

彭娟

谭胜蓝

周宏灏

李智

机构：

[1] 中南大学临床药理研究所

来源：

中国药理学通报 | 2013年 / 29卷 / 02期

基金：

国家高技术研究发展计划(863计划);

关键词：

华法林; 个体化治疗; 基因多态性; 剂量模型; VKORC1; CYP2C9;

D O I：

暂无

中图分类号：

R96 [药理学];

学科分类号：

100602 ; 100706 ;

摘要：

华法林是临床使用最广泛的口服抗凝药,其治疗窗窄,剂量个体差异大,容易发生出血或栓塞的风险。CYP2C9和VKORC1基因多态性明显影响华法林剂量。其他参与维生素摄入和循环,华法林转运的基因变异,以及microRNA也可能影响华法林剂量。该文结合国内外各种华法林稳定剂量预测模型研究,总结影响华法林剂量相关基因的最新研究进展,旨在为华法林个体化治疗提供参考和指导依据。

引用

页码：169 / 172

页数：4

共 14 条

[1] CYP450氧化还原酶的遗传多态对药物代谢的影响
范岚
彭向东
郭志华
周宏灏
[J]. 中国药理学通报, 2009, (09) : 1131 - 1133
[2] CYP3A4,CYP3A5和MDR1基因多态性对环孢素处置的影响
胡永芳
周宏灏
[J]. 中国药理学通报, 2005, (03) : 257 - 261
[3] Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients
Zhong, Shi-Long
Yu, Xi-Yong
Liu, Yuan
Xu, Dan
Mai, Li-Ping
Tan, Hong-Hong
Lin, Qiu-Xiong
Yang, Min
Lin, Shu-Guang
[J]. PHARMACOGENETICS AND GENOMICS, 2012, 22 (03) : 176 - 182
[4] Development and Comparison of a Warfarin-Dosing Algorithm for Korean Patients With Atrial Fibrillation
Cho, Hyun-Jung
On, Young-Keun
Bang, Oh Young
Kim, Jong-Won
Huh, Wooseong
Ko, Jae-Wook
Kim, June Soo
Lee, Soo-Youn
[J]. CLINICAL THERAPEUTICS, 2011, 33 (10) : 1371 - 1380
[5] VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China[J] . Qiang Gu,Yan Kong,J?rn Schneede,Ying-Bin Xiao,Lin Chen,Qian-Jin Zhong,Xue-Feng Wang,Jia Hao,Bai-Cheng Chen,Jing-Jin Chen.European Journal of Clinical Pharmacology . 2010 (12)
[6] CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement[J] . Han‐JingCen,Wu‐TaoZeng,Xiu‐YuLeng,MinHuang,XiaoChen,Jia‐LiLi,Zhi‐YingHuang,Hui‐ChangBi,Xue‐DingWang,Yan‐LingHe,FanHe,Rui‐NaZhou,Qi‐ShanZheng,Li‐ZiZhao.British Journal of Clinical Pharmacology . 2010 (2)
[7] Combined CYP2C9 , VKORC1 and CYP4F2 frequencies among racial and ethnic groups[J] . Stuart A Scott,Rame Khasawneh,Inga Peter,Ruth Kornreich,Robert J Desnick.Pharmacogenomics . 2010 (6)
[8] Genetic determinants of warfarin dosing in the Han-Chinese population
Lee, M. T. Michael
Chen, Chien-Hsiun
Chou, Ching-Heng
Lu, Liang-Suei
Chuang, Hui-Ping
Chen, Ying-Ting
Saleem, Amir N.
Wen, Ming-Shien
Chen, Jin-Jer
Wu, Jer-Yuarn
Chen, Yuan-Tsong
[J]. PHARMACOGENOMICS, 2009, 10 (12) : 1905 - 1913
[9] Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients
Ohno, Masako
Yamamoto, Akiko
Ono, Ayumu
Miura, Genta
Funamoto, Masanobu
Takemoto, Yasuhiko
Otsu, Kinya
Kouno, Yasushi
Tanabe, Tomoko
Masunaga, Yuiko
Nonen, Shinpei
Fujio, Yasushi
Azuma, Junichi
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (11) : 1097 - 1103
[10] Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients[J] . Sheng-Wen Huang,Hai-Sheng Chen,Xian-Qun Wang,Ling Huang,Ding-Li Xu,Xiao-Jia Hu,Zhi-Hui Huang,Yong He,Kai-Ming Chen,Dao-Kang Xiang,Xiao-Ming Zou,Qiang Li,Li-Qin Ma,Hao-Fei Wang,Bao-Lin Chen,Liang Li,Yan-Kai Jia,Xiang-Min Xu.Pharmacogenetics and Genomics . 2009 (3)

← 1 2 →